Assessment of cannabis use disorders: a systematic review of screening and diagnostic instruments.

BACKGROUND: Cannabis use and misuse have become a public health problem. There is a need for reliable screening and assessment tools to identify harmful cannabis use at an early stage. We conducted a systematic review of published instruments used to screen and assess cannabis use disorders. METHOD: We included papers published until January 2013 from seven different databases, following the PRISMA guidelines and a predetermined set of criteria for article selection. Only tools including a quantification of cannabis use and/or a measurement of the severity of dependence were considered. RESULTS: We identified 34 studies, of which 25 included instruments that met our inclusion criteria: 10 scales to assess cannabis use disorders, seven structured interviews, and eight tools to quantify cannabis use. Both cannabis and substance use scales showed good reliability and were validated in specific populations. Structured interviews were also reliable and showed good validity parameters. Common limitations were inadequate time-frames for screening, lack of brevity, undemonstrated validity for some populations (e.g., psychiatric patients, female gender, adolescents), and lack of relevant information that would enable routine use (e.g., risky use, regular users). Instruments to quantify consumption did not measure grams of the psychoactive compounds, which hampered comparability among different countries or regions where tetrahydrocannabinol concentrations may differ. CONCLUSIONS: Current instruments available for assessing cannabis use disorders need to be further improved. A standard cannabis unit should be studied and existing instruments should be adapted to this standard unit in order to improve cannabis use assessment.

Neurosífilis en pacientes portadores y no portadores de VIH: descripción y comparación de dos cohortes históricas / Neurosyphilis in the patients with and without HIV infection: description and comparison of two historical cohorts

Neurosyphilis follows a more aggressive and different clinical course in HIV-infected patients compared to patients with normal immunity. Two historical series of patients with a diagnosis of neurosyphilis between 1995 and 2008 were compared: they included a group of 15 patients with y and 28 patients without HIV infection. Probability of neurosyphilis in patients with positive serum VDRL was increased in patients infected with HIV comparedto HIV negative patients (OR: 62.37 IC:95 percent (32.1-119.1) p value:< 0,001). Predominant clinical manifestations in neurosyphilis in the HIV negative group were ocular abnormality, vascular encephalic and spinal cord lesions. In the HIV positive group, they were fever, ocular abnormalities and headache. There were no differences in cerebrospinal fluid characteristics between both groups. Neurosyphilis was diagnosed even in patients with blood VDRL of < 1:32, that happened in 17.8 percent of the HIV positive patients with blood and in 60 percent of t he HIV negative patients. Penicillin sodium given at dose ¡Ý than 18.000.000 IU/day IV during 14 days was the most common treatment. In patients with clinical neurosyphilis, 93 percent of HIV negative group, and 54.2 percent of HIV positive group had persistent neurological after-effects. Three HIV positive patients died due to causes not related to neurosyphilis.

[Hepatitis B, C, Treponema pallidum and Toxoplasma gondii co-infections in HIV infected patients]. / Coinfecciones por virus hepatitis B, virus hepatitis C, Treponema pallidum y Toxoplasma gondii en la cohorte de pacientes VIH positivos en control en la Pontificia Universidad Católica de Chile.

BACKGROUND: Some infections share common modes of transmission with HIV and have the potential to change the course of the latter. AIM: To assess the prevalence of hepatitis B virus (HBV) hepatitis C virus (HCV), Treponema palladium and Toxoplasmosis gondii co-infections in HIV-1 infected patients followed at a university hospital. MATERIAL AND METHODS: Clinical records of HIV-positive individuals were reviewed. The analysis included: demographical data, hepatitis B surface antigen (HBsAg), IgM and IgG anti-HBc, antibodies, anti-HCV antibodies, RPR or VDRL test and IgG anti Tgondii antibodies. RESULTS: Three hundred ninety five patients (aged 16 to 89 years, 359 males) were included in the review. Seventy nine percent had been tested for HBV status with HBsAg, and the global HIV-HBV co-infection prevalence was 6.1%. A subgroup of 190 individuals were tested for HBV infection with HBsAg and IgM/IgG anti-HBc markers. Of these, 46% fulfilled co-infection criteria: eight with acute hepatitis B, 11 with chronic hepatitis B and 69 with inactive HBV infection. The frequency of HIV-HBV co-infection was 48% and 22% among men and women respectively (NS). HCV-HN co-infection was detected in 3%, syphilis-HIV co-infection in 21% and T gondii-HIV co-infection in 26%. CONCLUSIONS: In this cohort, HIV infection is accompanied by a high prevalence of other co-infections, particularly HBV among men.

[Tuberculosis in HIV positive individuals]. / Tuberculosis en el paciente con infección por virus de inmunodeficiencia humana.

Tuberculosis (TB) is worldwide one of the leading causes of death in HIV infected individuals. In Chile, TB rates have fallen dramatically in the general population and new cases are being progressively restricted to high risk groups, particularly immunosuppressed individuals. In these patients diagnostic tests have decreased sensitivity and TB frequently evolves to disseminated and rapidly progressive forms. Besides, the concurrent treatment of HIV infection and TB adds further toxicities and the possibility of significant interactions. In this article we review the particularities and advances in diagnostic and therapeutic aspects of TB in the HIV infected patient.

Coinfecciones por virus hepatitis B, virus hepatitis C, Treponema pallidum y Toxoplasma gondii en la cohorte de pacientes VIH positivos en control en la Pontificia Universidad Católica de Chile / Hepatitis B, C, Treponema pallidum and Toxoplasma gondii co-infections in HIV infected patients

Background: Some infections share common modes of transmission with HIV and have the potential to change the course of the latter. Aim: To assess the prevalence of hepatitis B virus (HBV) hepatitis C virus (HCV), Treponema palladium and Toxoplasmosis gondii co-infections in HIV-1 infected patients followed at a university hospital. Material and methods: Clinical records of HIV-positive individuals were reviewed. The analysis included: demographical data, hepatitis B surface antigen (HBsAg), IgM and IgG anti-HBc, antibodies, anti-HCV antibodies, RPR or VDRL test and IgG anti Tgondii antibodies. Results: Three hundred ninety five patients (aged 16 to 89years, 359 males) were included in the review. Seventy nine percent had been tested for HBV status with HBsAg, and the global HIV-HBV co-infection prevalence was 6.1 percent. A subgroup of190 individuals were tested for HBV infection with HBsAg and IgM/IgG anti-HBc markers. Of these, 46 percent fulfilled co-infection criteria: eight with acute hepatitis B, 11 with chronic hepatitis B and 69 with inactive HBV infection. The frequency of HIV-HBV co-infection was 48 percent and 22 percent among men and women respectively (NS). HCV-HN co-infection was detected in 3 percent, syphilis-HIV co-infection in 21 percent and T gondii-HIV co-infection in 26 percent. Conclusions: In this cohort, HIV infection is accompanied by a high prevalence of other co-infections, particularly HBV among men.

Tuberculosis en el paciente con infección por virus de inmunodeficiencia humana / Tuberculosis in HIV positive individuals

Tuberculosis (TB) is worldwide one of the leading causes of death in HIV infected individuals. In Chile, TB rates have fallen dramatically in the general population and new cases are being progressively restricted to high risk groups, particularly immunosupressed individuals. In these patients diagnostic tests have decreased sensitivity and TB frequently evolves to disseminated and rapidly progressive forms. Besides, the concurrent treatment of HIV infection and TB adds further toxicities and the possibility of significant interactions. In this article we review the particularities and advances in diagnostic and therapeutic aspeets of TB in the HIV infected patient.

La tuberculosis (TBC) es una de las principales causas de muerte en el mundo en individuos con infección por VIH. En Chile, su incidencia en la población general se ha reducido significativamente y esta enfermedad se ha ido centrando en grupos de alto riesgo, en particular los inmuno suprimidos. En estos pacientes las pruebas diagnósticas tienen sensibilidad inferior y la enfermedad evoluciona con mayor frecuencia hacia formas diseminadas y rápidamente progresivas. El tratamiento simultáneo de la infección por VIH y la enfermedad tuberculosa aumenta la complejidad al sumar toxicidades e interacciones. En este artículo revisamos las particularidades y los avances que han surgido, tanto en el diagnóstico como el tratamiento de la TBC, en el paciente co-infectado con VIH.

[Neurosyphilis in the patients with and without HIV infection: description and comparison of two historical cohorts]. / Neurosífilis en pacientes portadores y no portadores de VIH: descripción y comparación de dos cohortes históricas.

Neurosyphilis follows a more aggressive and different clinical course in HIV-infected patients compared to patients with normal immunity. Two historical series of patients with a diagnosis of neurosyphilis between 1995 and 2008 were compared: they included a group of 15 patients with y and 28 patients without HIV infection. Probability of neurosyphilis in patients with positive serum VDRL was increased in patients infected with HIV compared to HIV negative patients (OR: 62.37 IC:95% (32.1-119.1) p value:< 0,001). Predominant clinical manifestations in neurosyphilis in the HIV negative group were ocular abnormality, vascular encephalic and spinal cord lesions. In the HIV positive group, they were fever, ocular abnormalities and headache. There were no differences in cerebrospinal fluid characteristics between both groups. Neurosyphilis was diagnosed even in patients with blood VDRL of < 1:32, that happened in 17.8% of the HIV positive patients with blood and in 60% of t he HIV negative patients. Penicillin sodium given at dose >or= than 18.000.000 IU/day IV during 14 days was the most common treatment. In patients with clinical neurosyphilis, 93% of HIV negative group, and 54.2% of HIV positive group had persistent neurological after-effects. Three HIV positive patients died due to causes not related to neurosyphilis.